Li Guorong, Forest Fabien, Feng Gang, Gentil-Perret Anne, Péoc'h Michel, Cottier Michèle, Mottet Nicolas
Department of Urology, North Hospital, CHU de Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France; LINA, EA 4624, Faculty of Medicine, University of Jean-Monnet, Saint-Etienne, France.
Department of Pathology, North Hospital, CHU de Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France.
Urol Oncol. 2014 Nov;32(8):1272-6. doi: 10.1016/j.urolonc.2014.05.011. Epub 2014 Jul 1.
A disintegrin and metalloproteinase-17 (ADAM17) plays an important role in biological activity in different cancers. Its expression and prognostic value have not been studied in clear cell renal cell carcinoma (cRCC). The objective of this study was to explore the prognostic value of ADAM17 in patients with cRCC.
A total of 131 patients with cRCC were studied. There were 90 men and 41 women, with an average age of 67 years (range: 34-93 y). There were 110 patients with localized disease and 21 patients with metastatic disease. The expression of ADAM17 was evaluated by immunohistochemistry with a monoclonal antibody. The follow-up varied from 4.2 to 184 months, with a median of 72 months for patients with localized disease. Kaplan-Meier with a log-rank test was performed to compare the progression-free survival after surgery. The univariate and multivariate analyses were performed to examine the significance of ADAM17 expression for the patient's progression-free survival.
The ADAM17 expression was found in 109/131 tumors. The ADAM17 expression was found in 20/21 metastatic tumors and in 89/110 localized tumors. Regarding patients with localized tumors, 31 patients experienced a recurrence or death during follow-up. The Kaplan-Meier analysis revealed that the high expression of ADAM17 was associated with a reduced progression-free survival (P = 0.005). The univariate logistic regression analysis indicated that the high expression of ADAM17 was associated with the disease progression (hazard ratio = 2.826; 95% CI: 1.324-6.034; P = 0.007). The high expression of ADAM17 remained a significant factor for decreased progression-free survival in multivariate analysis.
ADAM17 was frequently expressed in cRCC. The high expression of ADAM17 was correlated with a worse outcome for patients with cRCC. ADAM17 is a new biomarker for the management of patients with cRCC.
解整合素金属蛋白酶17（ADAM17）在不同癌症的生物学活性中发挥重要作用。其在透明细胞肾细胞癌（cRCC）中的表达及预后价值尚未得到研究。本研究的目的是探讨ADAM17在cRCC患者中的预后价值。
共研究了131例cRCC患者。其中男性90例，女性41例，平均年龄67岁（范围：34 - 93岁）。110例为局限性疾病患者，21例为转移性疾病患者。采用单克隆抗体免疫组化法评估ADAM17的表达。随访时间从4.2个月至184个月不等，局限性疾病患者的中位随访时间为72个月。采用Kaplan-Meier法和对数秩检验比较术后无进展生存期。进行单因素和多因素分析以检验ADAM17表达对患者无进展生存期的意义。
131例肿瘤中有109例检测到ADAM17表达。21例转移性肿瘤中有20例检测到ADAM17表达，110例局限性肿瘤中有89例检测到ADAM17表达。对于局限性肿瘤患者，31例在随访期间出现复发或死亡。Kaplan-Meier分析显示，ADAM17高表达与无进展生存期缩短相关（P = 0.005）。单因素逻辑回归分析表明，ADAM17高表达与疾病进展相关（风险比 = 2.826；95%置信区间：1.324 - 6.034；P = 0.007）。在多因素分析中，ADAM17高表达仍然是无进展生存期降低的一个重要因素。
ADAM17在cRCC中经常表达。ADAM17高表达与cRCC患者较差的预后相关。ADAM17是cRCC患者管理的一种新生物标志物。
